Lucid Diagnostics Stock Buy Hold or Sell Recommendation
| LUCD Stock | USD 1.34 0.14 9.46% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Lucid Diagnostics is 'Hold'. Macroaxis provides Lucid Diagnostics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LUCD positions.
Check out Lucid Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide. Note, we conduct extensive research on individual companies such as Lucid and provide practical buy, sell, or hold advice based on investors' constraints. Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Lucid |
Execute Lucid Diagnostics Buy or Sell Advice
The Lucid recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lucid Diagnostics. Macroaxis does not own or have any residual interests in Lucid Diagnostics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lucid Diagnostics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Lucid Diagnostics Trading Alerts and Improvement Suggestions
| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics appears to be risky and price may revert if volatility continues | |
| Lucid Diagnostics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (2.22 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Morningstar |
Lucid Diagnostics Returns Distribution Density
The distribution of Lucid Diagnostics' historical returns is an attempt to chart the uncertainty of Lucid Diagnostics' future price movements. The chart of the probability distribution of Lucid Diagnostics daily returns describes the distribution of returns around its average expected value. We use Lucid Diagnostics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lucid Diagnostics returns is essential to provide solid investment advice for Lucid Diagnostics.
| Mean Return | 0.54 | Value At Risk | -5.21 | Potential Upside | 8.90 | Standard Deviation | 4.59 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lucid Diagnostics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lucid Stock Institutional Investors
| Shares | Lpl Financial Corp | 2024-12-31 | 53.4 K | Geneos Wealth Management Inc | 2024-12-31 | 29.6 K | Blackrock Inc | 2024-12-31 | 27.3 K | State Street Corp | 2024-12-31 | 27 K | Americana Partners, Llc | 2024-12-31 | 26.4 K | Xtx Topco Ltd | 2024-12-31 | 25.3 K | Two Sigma Securities, Llc | 2024-12-31 | 19.3 K | Jane Street Group Llc | 2024-12-31 | 13.8 K | Northern Trust Corp | 2024-12-31 | 13.1 K | Luminus Management, Llc | 2024-12-31 | 1 M | Vanguard Group Inc | 2024-12-31 | 560.9 K |
Lucid Diagnostics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (45.1K) | 53.5M | (31.2M) | (3.6M) | (3.2M) | (3.1M) | |
| Net Income | (8.3M) | (28.1M) | (56.2M) | (52.7M) | (47.4M) | (45.0M) | |
| End Period Cash Flow | 111.3K | 53.7M | 22.5M | 18.9M | 21.7M | 17.5M | |
| Change To Netincome | 173.9K | 65.5K | 9.6M | 13.9M | 15.9M | 16.7M | |
| Investments | (10.3K) | (862K) | (4.1M) | (249K) | (224.1K) | (235.3K) | |
| Free Cash Flow | (5.6M) | (18.5M) | (30.6M) | (33.0M) | (29.7M) | (28.2M) | |
| Other Non Cash Items | (1.1M) | 10.5M | 653K | 4.9M | 5.6M | 3.2M |
Lucid Diagnostics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lucid Diagnostics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lucid Diagnostics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lucid stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.63 | |
β | Beta against Dow Jones | 1.05 | |
σ | Overall volatility | 4.66 | |
Ir | Information ratio | 0.14 |
Lucid Diagnostics Volatility Alert
Lucid Diagnostics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lucid Diagnostics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lucid Diagnostics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lucid Diagnostics Fundamentals Vs Peers
Comparing Lucid Diagnostics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lucid Diagnostics' direct or indirect competition across all of the common fundamentals between Lucid Diagnostics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lucid Diagnostics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lucid Diagnostics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lucid Diagnostics to competition |
| Fundamentals | Lucid Diagnostics | Peer Average |
| Return On Equity | -10.08 | -0.31 |
| Return On Asset | -1.01 | -0.14 |
| Operating Margin | (9.98) % | (5.51) % |
| Current Valuation | 134.01 M | 16.62 B |
| Shares Outstanding | 59.34 M | 571.82 M |
| Shares Owned By Insiders | 63.80 % | 10.09 % |
| Shares Owned By Institutions | 7.60 % | 39.21 % |
| Number Of Shares Shorted | 1.04 M | 4.71 M |
| Price To Book | 2.16 X | 9.51 X |
| Price To Sales | 18.42 X | 11.42 X |
| Revenue | 2.43 M | 9.43 B |
| Gross Profit | (2.22 M) | 27.38 B |
| EBITDA | (49.75 M) | 3.9 B |
| Net Income | (52.67 M) | 570.98 M |
| Cash And Equivalents | 34.46 M | 2.7 B |
| Cash Per Share | 0.89 X | 5.01 X |
| Total Debt | 15.26 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 4.55 X | 2.16 X |
| Book Value Per Share | (0.96) X | 1.93 K |
| Cash Flow From Operations | (32.82 M) | 971.22 M |
| Short Ratio | 2.11 X | 4.00 X |
| Earnings Per Share | (1.12) X | 3.12 X |
| Target Price | 3.5 | |
| Number Of Employees | 70 | 18.84 K |
| Beta | 1.34 | -0.15 |
| Market Capitalization | 77.15 M | 19.03 B |
| Total Asset | 27.27 M | 29.47 B |
| Retained Earnings | (150.74 M) | 9.33 B |
| Working Capital | (7.31 M) | 1.48 B |
| Net Asset | 27.27 M |
Note: Acquisition by Michael Gordon of 300000 shares of Lucid Diagnostics subject to Rule 16b-3 [view details]
Lucid Diagnostics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lucid . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Lucid Diagnostics Buy or Sell Advice
When is the right time to buy or sell Lucid Diagnostics? Buying financial instruments such as Lucid Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lucid Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run IT Thematic Idea Now
IT
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lucid Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 0.497 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.